The guidelines neither endorse nor discourage the use of genomic classifiers in diagnosing IPF or other ILDs, leaving considerable variability in clinical practice, often relying on expert opinion. Similar to Dr. @Southern, we primarily employ genomic classifiers in patients with indeterminate HRCT ...

Antifibrotics are indicated for the treatment of IPF, scleroderma-ILD, and progressive pulmonary fibrosis, not specifically for "UIP," which can manifest in any of the three. When a patient presents with an indeterminate pattern on CT without suggestive features of connective tissue disease on hist...

Yes, we utilize the genomic classifier in cases where the pattern is indeterminate for UIP, and occasionally when distinguishing between NSIP and UIP, or in tandem with BAL and TBBx when HP is under consideration. However, this is only done when the pre-test probability for UIP is significant. Given...